Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

It is also FDA-authorised under an EUA as a third primary series dose in individuals 12 years old and above who have certain kinds of immunocompromises. The Pfizer/BioNTech bivalent COVID-19 ...

As the state faces a multimillion dollar measles outbreak in West Texas, the House Public Health Committee passes HB 1586 ...

Australian scientists have revealed why receiving a booster vaccine in the same arm as your first dose is more effective.

Pfizer’s dose-optimization studies of once-daily formulations of danuglipron (NCT06567327 and NCT06568731) met key pharmacokinetic objectives and confirmed a formulation and dose with the ...

Pfizer said it halted development of danuglipron after discovering that a "participant in one of the dose-optimization studies experienced potential drug-induced liver injury." (REUTERS/Carlo ...

Pfizer (PFE) said Monday it will no longer develop its investigational pill for weight loss after detecting a "potential drug-induced liver injury" in a dose-optimization study participant.

Pfizer (NYSE:PFE) is overhauling its cardiometabolic ... was the right decision for the company after a patient in a dose-optimization study developed liver injury. He added that Pfizer would ...